Related Experiment Video
Updated: Sep 12, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Severe Mycoplasma Pneumoniae Infections During the 2023-2024 Outbreak: A Single-Center Descriptive Study in a
Ana Espeleta-Fox1, Alberto García-Salido, José Luis De Unzueta-Roch
1From the Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
None:
In this brief report, we describe Mycoplasma pneumoniae infections admitted to our pediatric intensive care unit during 2023-2024. We compare with the previous 6 years and analyze their treatments and outcomes. We observe an increase of cases, half of them with underlying conditions. Hypoxemia was their main severity sign. Viral coinfections were common. Bacterial coinfections appeared to worsen outcomes.
More Related Videos
06:04Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-III